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Background: Mucopolysaccharidosis type II (MPS II) is an X-linked recessive, multisystemic lysosomal storage
disorder caused by a deficiency of iduronate-2-sulfatase. MPS II has a variable age of onset and variable rate of
progression. In Asian countries, there is a relatively higher incidence of MPS II compared to other types of MPS.
Methods: A retrospective analysis was carried out of 34 Taiwanese MPS II patients who died between 1995 and
2012. The clinical characteristics, medical records, age at death, and cause of death were evaluated to better
understand the natural progression of this disease.
Results: The mean age at death of 31 of the patients with a severe form of the disease with significant cognitive
impairment was 13.2 ± 3.2 years, compared with 22.6 ± 4.3 years in the three patients with a mild form of the
disease without cognitive involvement (n = 2) or the intermediate form (n = 1) (p < 0.001). The mean ages at onset
of symptoms and confirmed diagnosis were 2.5 ± 2.1 and 4.8 ± 3.1 years, respectively (n = 32). Respiratory failure was
the leading cause of death (56 %), followed by cardiac failure (18 %), post-traumatic organ failure (3 %), and
infection (sepsis) (3 %) (n = 27). Age at onset of symptoms was positively correlated with life expectancy (p < 0.01).
Longevity gradually increased over time from 1995 to 2012 (p < 0.05).
Conclusions: Respiratory failure and cardiac failure were the two major causes of death in these patients. The life
expectancy of Taiwanese MPS II patients has improved in recent decade.
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Mucopolysaccharidosis type II (MPS II; Hunter syn-
drome; OMIM +309900) is an X-linked recessive, multi-
systemic lysosomal storage disorder caused by deficient
activity of iduronate-2-sulfatase (IDS), which catalyzes a
sequential step in the catabolism of glycosaminoglycans
(GAGs), heparan sulfate and dermatan sulfate. The accu-
mulation of GAGs in the lysosomes of many organs and
tissues causes progressive cellular dysfunction, alters the
development of vital organs and the skeleton, and in* Correspondence: 4535lin@gmail.com
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adolescence. MPS II has a variable age at onset and vari-
able rate of progression. Patients with severe MPS II
usually present between 2 and 4 years of age with coarse
facial features, airway obstruction, cardiomyopathy, car-
diac valve dysplasia, hepatosplenomegaly, joint stiffness,
skeletal deformities, hernias, recurrent ear, nose, and
throat infections, and progressive neurological involve-
ment, leading to profound cognitive impairment and
hyperactivity. Patients with the mild form of the disease
are spared cognitive impairment, but still have other
somatic problems [1–3].
Hematopoietic stem cell transplantation (HSCT) is cur-
rently the only treatment to prevent progressive neurode-
generative disease in a select group of MPS disorders,le is distributed under the terms of the Creative Commons Attribution 4.0
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by a high risk of graft failure and transplantation-related
morbidity and mortality [4–6]. Over the last few years, en-
zyme replacement therapy (ERT) with recombinant IDS
(idursulfase; Elaprase, Shire Human Genetic Therapies,
Cambridge, MA, USA) has been licensed in the United
States and the European Union for the treatment of MPS
II, and been shown to improve endurance, joint mobility,
and lung function, and to potentially be beneficial for
many patients with MPS II, especially if started early in
the course of the disease [2, 7–9].
The incidence of MPS II differs among different popula-
tions, with reported rates ranging from 1.39 in 100,000
male live births in Northern Ireland [10] to 0.19 in
100,000 male live births in British Columbia [11]. Asian
countries have a higher reported incidence of MPS II
compared to other types of MPS, and in Taiwan the inci-
dence of MPS II is approximately 2.05 in 100,000 male live
births [12, 13]. A founder effect may account for the varia-
tions in the incidence in different ethnic populations.
Only a handful of reports have described the natural his-
tory and cause of death in patients with MPS II [14, 15],
including the Hunter Outcome Survey (HOS) [14]. Al-
though the enrolled cohort was large including 129 histor-
ical patients from 16 countries, only 3 % (n = 4) of those
enrolled were Asian. Another related study was by Sohn
et al. [15], who reported the natural history of 19 Korean
patients with MPS II who died. The purpose of this study
was to retrospectively collect and analyze data on the life
expectancy and causes of death as recorded on the medical
charts of Taiwanese MPS II patients who died between
1995 and 2012 to better understand the natural progres-
sion of this disease.
Methods
Study population
In order to acquire as much data as possible on all pa-
tients with MPS II in Taiwan who died from January
1995 to December 2012, the following sources were
used: (1) Membership list of Taiwan MPS Society (pa-
tient support group); (2) Medical records from 8 medical
centers in Taiwan, including Mackay Memorial Hospital,
Taipei; National Cheng Kung University Hospital, Tainan;
Kaohsiung Veterans General Hospital; National Taiwan
University Hospital, Taipei; China Medical University
Hospital, Taichung; Chi Mei Medical Center, Tainan;
Taipei Veterans General Hospital; and Chang Gung
Memorial Hospital, Taoyuan; (3) Laboratory records from
the Department of Medical Research, Mackay Memorial
Hospital, Taipei, Taiwan; and (4) Records from the Taiwan
Foundation for Rare Disorders.
The diagnosis of all patients was confirmed by two-
dimensional electrophoresis of urinary GAGs and a defi-
ciency of IDS activity measured in peripheral leukocytesor fibroblasts [16, 17]. The clinical characteristics, med-
ical records, age at death, and cause of death of these
patients were retrospectively reviewed. The hospital’s
ethics committee approved the study. All of the patients
or their parents provided written informed consent.
Data and statistical analysis
Descriptive statistics were performed, and the results are
presented as mean ± standard deviation unless otherwise
indicated. The relationships between life expectancy and
year of death as well as age at onset of symptoms in
these MPS II patients were evaluated using Pearson’s
correlation coefficient (r), and testing for statistical sig-
nificance (p < 0.05) was performed using Fisher’s r-z
transformations. All statistical analyses were performed
with SPSS version 11.5 (SPSS Inc., Chicago, Illinois,
USA). Statistical significance was set at p < 0.05.
Results
From January 1995 to December 2012, we identified 34
patients with MPS II who died. Among these patients,
31 had a severe form of disease with significant cognitive
impairment, two had a mild form without cognitive in-
volvement, and 1 had an intermediate form. In this co-
hort, two patients (No. 1 and No. 6) had received HSCT.
Patient No. 1 received HSCT twice in 1999 and 2001,
however, he died at the age of 5.4 years due to infection
and sepsis. Patient No. 6 received HSCT in 1995 at
10 years of age, however he died at the same year due to
cardiac failure. Only two patients (No. 28 and No. 33)
had received ERT. Patient No. 28 received ERT for 1 year
from September 2007 to September 2008, however he
died in December 2009 at 17.7 years of age due to car-
diac failure. Patient No. 33 received ERT for 1 month
just before his death at the age of 24.1 years due to car-
diac failure (Table 1). The mean age at death of all pa-
tients was 14.2 ± 4.2 years (median age 13.4 years), and
the mean ages at onset of symptoms and confirmed
diagnosis were 2.5 ± 2.1 and 4.8 ± 3.1 years, respectively
(n = 32). The mean gestational age and birth weight were
39.2 ± 1.8 weeks and 3522 ± 581 grams, respectively (n =
24). The mean standard deviation score of birth weight
was 0.56 ± 1.30 (n = 24). The primary cause of death was
identified in 27 patients, while 7 patients (21 %) died
without a definite cause being recorded. Respiratory fail-
ure was the leading cause (56 %) of death, followed by
cardiac failure (18 %), post-traumatic organ failure (3 %),
and infection (sepsis) (3 %) (Table 2). The mean age at
death of the 31 patients with the severe form was 13.2 ±
3.2 years, compared with 22.6 ± 4.3 years in the three pa-
tients with the mild or intermediate forms (p < 0.001).
Longevity also gradually increased over time from 1995
to 2012 (p < 0.05) (Fig. 1a). To further investigate this
trend, we divided the year of death into four groups:


























1 II (S) M 5.4 2003 0.1 0.3 37 2800 Infection
(sepsis)
– 1.1 and 3.1,
respectively
2 II (S) M 9.0 1997 4.5 7 NA NA Unknown – –
3 II (S) M 9.5 2005 1.3 3.6 38 4700 Respiratory failure – –
4 II (S) M 9.5 2008 0.1 1.2 37 2856 Respiratory failure – –
5 II (S) M 9.8 2011 2.6 2.6 39 3450 Respiratory failure – –
6 II (S) M 10.0 1995 0.2 9.3 41 3700 Cardiac failure – 9.6
7 II (S) M 11.3 2002 5.4 5.8 41 3200 Respiratory failure – –
8 II (S) M 11.7 2007 2.5 3 40 3250 Respiratory failure – –
9 II (S) M 11.9 1999 3 5.3 36 2800 Unknown – –
10 II (S) M 11.9 2003 0.7 1.3 35 3150 Respiratory failure – –
11 II (S) M 12.2 2002 0.2 5.1 39 3750 Respiratory failure – –
12 II (S) M 12.4 2007 1 2.8 41 3900 Respiratory failure – –
13 II (S) M 12.5 2009 1.3 1.3 NA NA Respiratory failure – –
14 II (S) M 12.9 2002 5 6.7 38 4200 Unknown – –
15 II (S) M 13.0 2003 1.7 5.0 40 3200 Respiratory failure – –
16 II (S) M 13.1 1997 0.1 5 39 3870 Cardiac failure – –
17 II (S) M 13.4 2001 NA NA NA NA Respiratory failure – –
18 II (S) M 13.4 2004 3.6 5.5 40 3500 Respiratory failure – –
19 II (S) M 13.9 2008 0.1 3.3 37 2400 Unknown – –
20 II (S) M 14.3 2003 3 10.6 42 3695 Respiratory failure – –
21 II (S) M 14.8 2010 1.2 1.5 40 3000 Cardiac failure – –
22 II (S) M 15.1 2005 4.5 7.6 40 3000 Respiratory failure – –
23 II (S) M 15.5 2009 3 3 NA NA Unknown – –
24 II (S) M 15.6 2012 3 4 40 3550 Unknown – –
25 II (S) M 16.1 2012 2.7 3.2 NA NA Respiratory
failure
– –
26 II (S) M 16.1 2010 0.2 2 40 4150 Respiratory failure – –
27 II (S) M 17.2 2002 3 12.2 NA NA Post-traumatic
organ failure
– –
28 II (I) M 17.7 2009 4.2 4.3 40 3750 Cardiac failure 15.4 –
29 II (S) M 17.8 2007 NA NA NA NA Unknown – –
30 II (S) M 18.0 2008 3.3 3.3 41 4500 Respiratory failure – –
31 II (S) M 18.9 2011 2.9 2.9 NA NA Respiratory failure – –
32 II (S) M 19.4 2007 3.3 3.3 40 4160 Respiratory failure – –
33 II (M) M 24.1 2009 10.1 10.1 NA NA Cardiac failure 23.9 –
34 II (M) M 25.9 2006 2 10.8 NA NA Cardiac failure – –
MPS mucopolysaccharidosis, ERT enzyme replacement therapy, HSCT hematopoietic stem cell transplantation, (S) severe form, (I) intermediate form, (M) mild form,
NA not available
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mean ages at death were 11 years (1995-2000, n = 4),
12.5 years (2001-2004, n = 10), 15.3 years (2005-2008,
n = 10), and 16.1 years (2009-2012, n = 10), respect-
ively (Fig. 1b). The age at onset of symptoms was
positively correlated with life expectancy (p < 0.01) (Fig. 2).Discussion
Only a few studies have reported the survival and causes
of death of patients with MPS II [14, 15], and to the best
of our knowledge, this is the first multicenter study to
analyze the life expectancy and causes of death of pa-
tients with MPS II in Taiwan. We found that the life
Table 2 Clinical characteristics of the 34 Taiwanese patients
with MPS II who died between 1995 and 2012
Clinical characteristics Number (%)
Age at onset of symptoms (years) (n = 32) 2.5 ± 2.1
Age at diagnosis (years) (n = 32) 4.8 ± 3.1
Gestational age (weeks) (n = 24) 39.2 ± 1.8
Birth weight (gram) (n = 24) 3522 ± 581
Birth weight (SDS) (n = 24) 0.56 ± 1.30
Primary cause of death, n (%)
Respiratory failure 19 (56 %)
Cardiac failure 6 (18 %)
Post-traumatic organ failure 1 (3 %)
Infection (sepsis) 1 (3 %)
Unknown 7 (21 %)
Age at death (years) 14.2 ± 4.2
Age at death, n (%)
<5 years 0
≧5 to <10 years 5 (15 %)
≧10 to <15 years 16 (47 %)
≧15 to <20 years 11 (32 %)
≧20 years 2 (6 %)
Year of death, n (%)
1995–2000 4 (12 %)
2001–2004 10 (29 %)
2005–2008 10 (29 %)
2009–2012 10 (29 %)
Phenotype, n (%)
Severe 31 (91 %)
Intermediate 1 (3 %)
Mild 2 (6 %)
ERT, n (%)
Yes 2 (6 %)
No 32 (94 %)
HSCT, n (%)
Yes 2 (6 %)
No 32 (94 %)
MPS mucopolysaccharidosis, SDS standard deviation score, ERT enzyme
replacement therapy, HSCT hematopoietic stem cell transplantation
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cades. With the implementation of the National Health In-
surance program in Taiwan in 1995, it is possible that this
improvement may be due to referral of these patients to
specialists and improvements in multidisciplinary care. We
also found that the patients with cognitive impairment had
a shorter life span than those without cognitive impair-
ment, which is consistent with previous reports [14, 15].
The most severely affected patients with MPS II usu-
ally only survive until the second decade of life, however,less severely affected patients may survive until the fifth
or sixth decades of life [2]. In a study by Jones et al. [14]
on 129 patients from the HOS, the median age of death
was 13.4 years, compared to 16.8 years in a study by
Sohn et al. [15] on 19 Korean patients. The median age
of death in the current study was similar at 13.4 years.
Notably, all of the patients with the severe form of MPS
II in this study died before 20 years of age, with the old-
est age being 19.4 years.
For the patients with the mild form of MPS II without
cognitive impairment, the median ages at death were
14.6 years (n = 62) and 25.1 years (n = 4) in the studies
by Jones et al. [14] and Sohn et al. [15], respectively,
which are similar to the current study (25 years; n = 2).
Our previous cohort [12] showed that among 68
Taiwanese patients with MPS II diagnosed from 1984 to
2004, 49 (72 %) has the severe form with cognitive
impairment, and 19 (28 %) had the mild form without
cognitive impairment. According to Taiwanese govern-
mental policy, ERT is only subsidized by the National
Health Insurance program for MPS II patients who do
not have neurological involvement. At the time of writ-
ing this study, 18 patients with the mild form of MPS II
without neurological involvement are receiving ERT in
Taiwan. Because most Taiwanese MPS II patients with
the mild form are still alive, only two patients with the
mild form (6 %) who died were enrolled in this study.
Thus, the present study may not completely reflect the
true survival rate of Taiwanese patients with the mild
form of MPS II. In addition, since ERT for MPS II
patients has been shown to substantially improve endur-
ance, joint mobility, cardiac hypertrophy, and lung func-
tion [2, 7–9, 18], the length of survival and natural
course of these patients may be significantly altered by
ERT. Because only two patients in this study had re-
ceived ERT (for 1 year and 1 month, respectively), the
effects of ERT on mortality in these patients is not clear.
Therefore, further multicenter studies with larger co-
horts and a longer follow-up period are warranted.
HSCT is not indicated for patients with MPS II due to
significant morbidity and mortality as well as no obvious
efficacy shown in cognitive involvement [19, 20]. How-
ever, Tanaka et al. [6] performed a nationwide retro-
spective study in Japan on the efficacy of HSCT in 21
MPS II patients, and reported that HSCT was effective for
brain or heart involvement when performed before signs
of brain atrophy or valvular regurgitation. In the current
study, two patients (No. 1 and No. 6) had received HSCT.
Patient No. 1 received HSCT twice in 1999 and 2001,
however he died at 5.4 years of age due to infection and
sepsis. Patient No. 6 received HSCT in 1995 at 10 years of
age, however he died the same year due to cardiac failure.
The poor outcome of the latter patient may be due to the
older age at the time of HSCT.
Fig. 1 Life-span of Taiwanese MPS II patients who died between 1995 and 2012. a Age at death by individual patient. b Mean age at death over time.
The life-span increased gradually over time (p < 0.05). MPS, mucopolysaccharidosis; (M), mild form; (I), intermediate form; (S), severe form
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MPS, and airway-related morbidity and mortality is
common, as reported in the HOS for MPS II. Cardiac
dysfunction due to structural damage can also signifi-
cantly increase the morbidity and mortality of affectedFig. 2 The relationship between age at onset of symptoms and life-span o
onset of symptoms was positively correlated with life expectancy (p < 0.01)patients [14, 21–23]. The leading cause of death in the
HOS (n = 129) was airway problems (n = 59, 46 %),
followed by cardiac problems (n = 20, 16 %) [14]. Sohn
et al. [15] reported that the leading cause of death was
pneumonia (n = 5, 26 %) among 19 patients with MPS II,f Taiwanese MPS II patients who died between 1995 and 2012. Age at
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coronary artery stenosis. In the current study, respira-
tory failure was the primary cause of death (n = 19,
56 %), followed by cardiac failure (n = 6, 18 %), which is
consistent with the previous studies.
Różdżyńska-Świątkowska et al. [24] reported that many
MPS patients are larger than the general population at the
time of birth. Therefore, a high birth weight and/or large
for gestational age may raise the suspicion of MPS and
help to promptly identify the disease. In the present study,
the mean gestational age and birth weight were 39.2 ±
1.8 weeks and 3522 ± 581 grams, respectively (n = 24) with
a mean standard deviation score of birth weight of 0.56 ±
1.30 (n = 24), which is consistent with the previous studies.
Since MPS II is a rare, progressive and multisystemic
disease, as well as insidious initial signs and symptoms
in these patients, making an early diagnosis can be a
challenge for first-line general medical practitioner. Sohn
et al. [15] reported that the mean ages at onset of symp-
toms and at diagnosis in Korean MPS II patients were
3.3 years and 5.6 years, respectively (n = 75). The dur-
ation between these two time points is 2.3 years, which
is consistent with our findings (2.3 years).
In the current study, the age at onset of symptoms
was positively correlated with life expectancy (p < 0.01).
It is well known that MPS II has a wide spectrum of dis-
ease severity, and that patients with the milder form
may exhibit more insidious clinical signs and milder
symptoms as well as a longer survival.
In this study, the life expectancy of the patients in-
creased gradually over time from 1995 to 2012 (p < 0.05).
With the implementation of the National Health Insur-
ance program in Taiwan in 1995, it is possible that this
improvement in life expectancy is due to referral of the
patients to specialists and improvements in multidisciplin-
ary care. Similarly, Jones et al. [14] reported that the me-
dian age at death in the HOS was significantly lower in
the patients who died in or before 1985 compared
with those who died after 1985 (11.3 versus 14.1 years,
p < 0.001). Sohn et al. [15] also reported that the patients
who died after 2005 had a better survival than those who
died before 2005 (19.4 versus 11.4 years, p < 0.05). This
may reflect improvements in an early diagnosis, medical
care, and appropriate treatment for patients over the past
two decades.
Limitations
As a retrospective and multicenter study, some medical re-
cords were missing and not available at the time of this
study. In addition, the small sample size in this cohort re-
flects the rare nature of this genetic disorder, and the de-
gree of disease severity was quite variable. Therefore,
studies with a larger cohort with a longer follow-up period
are warranted.Conclusion
Respiratory failure and cardiac failure were the two
major causes of death for the patients with MPS II in
this study. The life expectancy of Taiwanese MPS II pa-
tients has improved in recent decades, possibly due to
referral of patients to specialists and improvements in
multidisciplinary care. These findings could serve as
baseline data for the analysis of the long-term effects of
ERT and HSCT on patients with MPS II, and to develop
quality of care strategies.
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